Speqta: Strategic Review Completed

Research Note

2022-03-17

07:53

Redeye retains its positive view on Speqta following the Strategic Review. We believe the significant cash dividend combined with investments in Bidbrain is a balanced low-risk approach that should satisfy most shareholders.

Fredrik Nilsson

Disclosures and disclaimers